3Using an established CRISPR-Cas mediated genome editing technique for streptomycetes, we 4 explored the combinatorial biosynthesis potential of the auroramycin biosynthetic gene cluster in 5 Streptomyces roseoporous. Auroramycin is a potent anti-MRSA polyene macrolactam. In addition, it 6 also displays antifungal activities, which is unique among structurally similar polyene macrolactams, 7 such as incednine and silvalactam. In this work, we employed different engineering strategies to target 8 glycosylation and acylation biosynthetic machineries within its recently elucidated biosynthetic pathway.
9Six auroramycin analogs with variations in C-, N-methylation, hydroxylation and extender units 10 incorporation were produced and characterized. By comparing the bioactivity profiles of these analogs,
11we determined that unique disaccharide motif of auroramycin is essential for its antimicrobial bioactivity.
12We further demonstrated that C-methylation of the 3, 5-epi-lemonose unit, which is unique among 13 structurally similar polyene macrolactams, is key to its antifungal activity. 14 15 16 17 19 proportion of current drugs being natural product or natural product-derived [1]. Advances in genome 20 editing and synthetic biology tools, together with natural product biosynthesis knowledge accumulated 21 over the decades, allows us to better predict, design and build pathways towards the synthesis of 22 natural products [2]. Earlier, we established a rapid and efficient CRISPR-Cas9 strategy for biosynthetic 23 gene cluster (BGC) editing and activation in streptomycetes [3, 4], which opens up opportunities for 24 combinatorial biosynthesis in native streptomycete hosts [5]. Compared to chemical syntheses, 25 combinatorial engineering of native biosynthetic pathways allows us to design and biosynthesize 26 structurally complex chemical analogs without traversing difficult multi-step and possibly low-yielding 27 chemical reactions, thus facilitating elucidation of structure-activity relationships towards an optimized 28 drug lead.In this study, we describe our efforts to engineer the BGC of antimicrobial compound auroramycin [6, 1 7] and characterize its structure activity relationship (SAR). Auroramycin (1) is a polyene macrolactam 2 that is doubly glycosylated. Sugars are attached in the order of xylosamine and 3, 5-epi-lemonose to 3 the polyketide core. Compared to structurally similar natural products (Figure 1), such as the doubly 4 glycosylated incednine [8] and monoglycosylated silvalactam [9], auroramycin is the only polyene 5 macrolactam with reported antifungal activity to date. One of the main structural differences between 6 auroramycin, incednine and silvalactam is their glycosylation pattern (Figure 1). Glycosylation can 7 significantly increase the diversity and complexity of natural products and has often been shown to 8 directly and significantly impact the their bioactivity and pharmacological properties [10, 11]. As such, 9 glycodiversification is an attractive strategy to diversify and optimize bioac...